Curated News
By: NewsRamp Editorial Staff
December 22, 2025
Soligenix Reports Positive Phase 2a Results for Psoriasis Therapy SGX302
TLDR
- Soligenix's SGX302 offers a noncarcinogenic photodynamic therapy advantage for psoriasis, potentially capturing market share with its well-tolerated, first-in-class treatment.
- SGX302 uses visible light-activated synthetic hypericin in an optimized gel formulation, applied twice weekly over 18 weeks with no drug-related adverse events reported.
- This therapy provides a safer, noncarcinogenic treatment option for psoriasis patients, improving quality of life through an enhanced patient experience and clinical efficacy.
- SGX302 introduces a novel photodynamic therapy using synthetic hypericin activated by visible light, representing an innovative approach to treating skin conditions.
Impact - Why it Matters
This news matters because it represents significant progress in developing safer treatment options for the approximately 125 million people worldwide affected by psoriasis. Current treatments often carry risks of carcinogenicity or systemic side effects, creating an urgent need for noncarcinogenic alternatives like SGX302's photodynamic therapy approach. The positive safety profile and clinical improvements observed in the Phase 2a trial suggest this could become an important new option for patients with mild-to-moderate psoriasis who seek effective local treatment without systemic risks. For the broader healthcare landscape, successful development of such therapies could reduce long-term healthcare costs associated with managing side effects of current treatments while improving patient quality of life through more convenient, targeted therapeutic approaches.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, has announced extended top line results from its Phase 2a clinical trial of SGX302 for mild-to-moderate psoriasis. The investigational therapy utilizes synthetic hypericin activated by visible light, representing a first-in-class photodynamic therapy mechanism. In the trial's third cohort, four additional patients received an optimized gel formulation designed to improve patient experience through easier dispensation and skin application. The company reported that SGX302 was well tolerated by all patients in this cohort, with no drug-related adverse events identified during the 18-week treatment period, during which the gel was applied twice weekly to psoriasis lesions.
The updated findings highlight clinical improvements with this enhanced formulation, underscoring the potential of SGX302 as a noncarcinogenic photodynamic treatment option. This development is particularly significant as it addresses the need for safer, non-systemic therapies for chronic skin conditions like psoriasis. The trial's progression into an extension cohort demonstrates continued momentum for this innovative approach, which could offer patients an alternative to traditional treatments that may carry carcinogenic risks or systemic side effects. For more detailed information about these promising results, readers can explore the comprehensive coverage available through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology and life sciences developments.
BioMedWire serves as a key resource for investors and industry professionals seeking timely information about companies like Soligenix, providing access to breaking news and insightful content through various distribution channels including article syndication to 5,000+ outlets and enhanced press release solutions. The platform's broad reach and specialized focus make it uniquely positioned to deliver important updates about clinical advancements like the SGX302 trial results to a wide audience of stakeholders. For those interested in following Soligenix's progress, the company maintains an active newsroom where the latest updates relating to SNGX are available, ensuring transparent communication about this potentially groundbreaking therapy for psoriasis patients.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Reports Positive Phase 2a Results for Psoriasis Therapy SGX302
